ArticleScientific reports2019
Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Molecular imaging of renal cell carcinomas: ready for prime time.Nature reviews. Urology · 2025Review
- Preclinical Characterization of DPI-4452: AJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Molecular Imaging Diagnosis of Renal Cancer UsingDiagnostics (Basel, Switzerland) · 2023Review
- Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine.European journal of nuclear medicine and molecular imaging · 2022Review
- Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3.Pharmaceutics · 2022Article
- New Developments in Carbonic Anhydrase IX-Targeted Fluorescence and Nuclear Imaging Agents.International journal of molecular sciences · 2022Review
- Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review.European urology · 2022Review
- Imaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy.Frontiers in oncology · 2021Review
- Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond.EJNMMI radiopharmacy and chemistry · 2020Review
- Affibody Molecules as Targeting Vectors for PET Imaging.Cancers · 2020Review
- CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbonic anhydrase IX (CAIX) is a cancer-associated molecular target for several classes of therapeutics. CAIX is overexpressed in a large fraction of renal cell carcinomas (RCC). Radionuclide molecular imaging of CAIX-expression might offer a non-invasive methodology for stratification of patients with disseminated RCC for CAIX-targeting therapeutics. Radiolabeled monoclonal antibodies and their fragments are actively investigated for imaging of CAIX expression. Promising alternatives are small non-immunoglobulin scaffold proteins, such as affibody molecules. A CAIX-targeting affibody ZCAIX:2 was re-designed with the aim to decrease off-target interactions and increase imaging contrast. The new tracer, DOTA-HE
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.